Skip to content
Subscriber Only
Opinion
Max Nisen

Will Donald Trump Stand Up to Seniors on Drug Prices?

Restricting access to expensive medicines should help lower Medicare costs, but it may exact a political price.

The status quo works for many seniors. 

The status quo works for many seniors. 

Photograph: AP GraphicsBank

President Donald Trump’s drug pricing-push is about to run into what might be its most potent opponent yet: America’s senior citizens. 

On Monday afternoon, the Trump administration released a proposal for rules that would make it easier for Medicare Part D prescription-drug plans to negotiate prices for a broader array of medicines than they do currently. That’s arguably a good thing. But in order for this effort to have a real impact, plans will likely have to be able to restrict the access that senior citizens have had for more than a decade to certain classes of drugs.